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a  b  s  t  r  a  c  t
We  showed  previously  that  the  number  and  time  of  spike–wave  discharges  (SWDs)  were  increased  after
intraperitoneal  (i.p.)  injection  of lipopolysaccharide  (LPS),  an  effect,  which  was  completely  abolished  by
cyclooxygenase-2  (COX-2)  inhibitor  indomethacin  (IND)  pretreatment  in  Wistar  Albino  Glaxo/Rijswijk
(WAG/Rij)  rats.  These  and  other  results  suggest  that  injection  of LPS  to genetically  absence  epileptic
animals,  such  as  WAG/Rij  rats, may  allow  us to investigate  relationships  between  absence  epilepsy  and
LPS  evoked  neuroinﬂammation  processes.  However,  LPS  may  evoke  different  effects  on  absence  epilep-
tic  activity  in various  animal  strains.  Thus,  to extend  our previous  results,  we  injected  two  doses  of LPS
(50  g/kg  and 350 g/kg i.p.)  alone  and  in  combination  with  IND (10  mg/kg  IND  i.p. +50 g/kg  LPS)  into
rats  of two  model  animal  strains  (WAG/Rij  rats;  GAERS  rats: Genetic  Absence  Epileptic  Rats  from  Stras-
bourg)  and  into  Long  Evans  rats. The  effects  of  treatments  on  SWD  number  and  SWD  duration  were
examined.  Both  doses  of  LPS  increased  the  SWD  number  and  the total  time  of SWDs  dose-dependently
during  the  whole  4-h  recording  period,  which  was  abolished  by  IND  pretreatment  in all  three  investigated
strains.  These  results  extend  our  previous  results  suggesting  that  our  methods  using  LPS injection  into
freely  moving  absence  epileptic  rats  is applicable  not  only  in  well-established  animal  models  of  absence
epilepsy  such  as WAG/Rij  rats  and  GAERS  rats  but  also in  Long  Evans  rats  to investigate  links  between
inﬂammation  and  absence  epilepsy.
© 2014 Elsevier  Inc.  All  rights  reserved.Abbreviations: AMPA receptor, alpha-amino-3-hydroxy-5-methyl-4-
soazolepropionic acid receptor; CNS, central nervous system; COX-2,
yclooxygenase-2; EEG, electroencephalogram; GAERS rats, Genetic Absence
pileptic Rats from Strasbourg; HVRS, high-voltage rhythmic spike; IL-1,
nterleukin-1 ; IL-1R, interleukin-1 receptor; IND, indomethacin; i.p., intraperi-
oneal; LPS, lipopolysaccharide; PGE2, prostaglandin E2; PTC day, post-treatment
ontrol day; SWD, spike–wave discharge; TLR4, Toll-like receptor 4; TNF-, tumor
ecrosis factor-; WAG/Rij rats, Wistar Albino Glaxo/Rijswijk rats.
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It has been shown that enhanced pro-inﬂammatory cytokine
levels can increase the susceptibility to epileptic seizure (Galic et al.,
2008; Vezzani et al., 2008). Indeed, pro-inﬂammatory cytokines
(e.g., interleukin-1  (IL-1) and tumor necrosis factor- (TNF-
)) synthesized by glial cells in the central nervous system (CNS)
elevate neuronal excitability (Rodgers et al., 2009; Vezzani et al.,
2008; Vezzani and Granata, 2005). Changes in IL-1 and TNF-
levels may  have a role in SWD  generation/precipitation in two ani-
mal  models of human absence epilepsy, GAERS rats and WAG/Rij
rats (Akin et al., 2011; Van Luijtelaar et al., 2012). Lipopolysaccha-
ride evokes rapid excitation in the cortex (Wang and White, 1999),
enhances seizure susceptibility (Sayyah et al., 2003), increases
absence epileptic activity and body temperature (Kovács et al.,
2006, 2011) and changes protein expression in the WAG/Rij rat
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rain (Györffy et al., 2014). These effects of LPS may  be mediated by
ncreased levels of pro-inﬂammatory cytokines and interleukin-1
eceptor/Toll-like receptor (IL-1R/TLR) signaling in the CNS (Turrin
t al., 2001; Vezzani et al., 2011).
Lipopolysaccharide, a cell wall component of gram-negative
acteria, belongs to the pathogen-associated molecular patterns
PAMPs) (Vezzani et al., 2011), which induce rapid synthesis of
ther cytokines and COX-2 via Toll-like receptor 4 (TLR4) evoked
nduction of transcriptional factors (e.g., nuclear factor B, NFB)
n the CNS (Vezzani and Granata, 2005). Systemic injection of
PS to rats is a well-studied and described way  for precipita-
ion of inﬂammatory reactions in the CNS (Vezzani and Granata,
005), which is also suitable for investigation of links between
mmune system and absence epileptic activity (Kovács et al., 2006).
ipopolysaccharide injected into genetically absence epileptic ani-
als such as WAG/Rij rats, the animal strain, which is one of the
ost appropriate animal model strains for the study of sponta-
eous childhood absence epilepsy (Depaulis and Van Luijtelaar,
005), could provide an opportunity for the investigation of the
elationships between non-convulsive types of epilepsies such
s absence epilepsy and LPS/cytokine evoked neuroinﬂammatory
rocesses (Kovács et al., 2006), which is still incompletely under-
tood. We  previously demonstrated that i.p. application of LPS
ose-dependently increased the absence epileptic activity in freely
oving WAG/Rij rats (Kovács et al., 2006). Other absence epilep-
ic animals may  also be promising models to investigate the links
etween inﬂammation and epilepsy. However, the effects of LPS
n absence epileptic activity in freely moving animals have not
een investigated in genetically epileptic GAERS rats and Long
vans rats. It was recently demonstrated that Long Evans rats
lso produce SWDs similarly to WAG/Rij rats and GAERS rats
Depaulis and Van Luijtelaar, 2005; Huang et al., 2012; Polack
nd Charpier, 2006; Shaw, 2004, 2007; Shaw et al., 2009; Van
uijtelaar et al., 2011) allowing the investigation of SWDs in this
train as well. Therefore, to validate and extend our previous
esults, in which we demonstrated the LPS induced increase in
bsence epileptic seizures in WAG/Rij rats (Kovács et al., 2006) we
njected two doses of LPS (50 g/kg and 350 g/kg i.p.) alone, and
0 g/kg LPS in combination with 10 mg/kg IND into WAG/Rij rats,
AERS rats and Long Evans rats to investigate the effects of treat-
ents on absence epileptic activity by detecting and evaluating
WDs.
. Materials and methods
.1. Animals
Eight months old male WAG/Rij rats, GAERS rats and Long Evans
ats (housed at the Department of Zoology, University of West
ungary, Savaria Campus, Szombathely, Hungary) were used in
he experiments. Animals were kept in groups of 3–4 under stan-
ard laboratory conditions (12:12 h light–dark cycle, light was on
rom 08.00 AM to 08.00 PM), with free access to food pellets and
ater. Rats were maintained in air-conditioned rooms at 22 ± 2 ◦C
nd were housed individually after surgery and during the experi-
ents.
Animal treatment and surgery procedures were carried out
ccording to the local ethical rules in accordance with the Hungar-
an Act of Animal Care and Experimentation (1998, XXVIII, section
43/1998) in conformity with the regulations for animal experi-
entation in the European Communities Council Directive of 24
ovember 1986 (86/609/EEC). All efforts were made to reduce
he number of animals used and to minimize pain and suffer-
ng.Bulletin 104 (2014) 7–18
2.2. Recording of absence epileptic activity and body temperature
2.2.1. Implantation of animals for EEG recording and body
temperature measuring
Wistar Albino Glaxo/Rijswijk rats (n = 20), GAERS rats (n = 20)
and Long Evans rats (n = 20) were anaesthetized by halothane-air
mixture (0.8–1%) and implanted with screw electrodes as described
earlier (Kovács et al., 2006). Brieﬂy, stainless steel screw elec-
trodes were placed into the bone above the frontal (AP: 2.0 mm;  L:
2.1 mm)  and parietal (AP: −6.5 mm;  L: 2.1 mm)  cortices (Paxinos
and Watson, 2005) for electroencephalogram (EEG) recording,
whereas a screw (ground) electrode was placed above the cere-
bellum. A stainless steel plate (3 mm × 4 mm,  one side insulated)
was used as a reference electrode which was implanted under the
skin and over the masseter muscle. All electrodes were soldered to
a ten-pin socket.
To detect the well-known effect of LPS and IND on body tem-
perature, aluminum holders containing thermo-resistors (Pt 100)
were placed above the frontal bone (Kovács et al., 2006) of three
– three animals of all animal groups (Table 1). We  measured the
body temperature with a thermometer (SUPERTECH, Hungary) in
each 10 min. Electrodes and aluminum holders were ﬁxed to the
skull bone with acrylic dental cement. Rats were allowed to recover
from surgery for 2 weeks.
2.2.2. EEG recording and SWD  scoring
Electroencephalogram was recorded by a differential biologi-
cal ampliﬁer (Bioamp4, Supertech Ltd., Pécs, Hungary) connected
to a CED 1401 mII  data capture and analysis device. Spike2 soft-
ware (CED, Cambridge, UK) was  used for recording the EEG. To
detect SWDs, frontal cortex – plate and parietal cortex – plate
leads were recorded. The bandwidth of the EEG signal ﬁltering was
0.53–150 Hz. The analog signal was  A/D converted at 1 kHz sam-
pling rate and raw EEG data were stored on a PC for further analysis
(Kovács et al., 2006).
The main properties of a typical SWD  of WAG/Rij rats, GAERS
rats and Long Evans rats (WAG/Rij/GAERS/Long Evans) are as fol-
lows: power spectra 7–11/7–9/6–12 Hz (Fig. 1b, d and f), amplitude
0.2–1.0/0.3–1.0/0.1–2.0 mV,  duration 1–30/5–60/1–40 s (Akman
et al., 2010; Coenen and Van Luijtelaar, 2003; Depaulis and Van
Luijtelaar, 2005; Polack and Charpier, 2006; Shaw, 2004). The num-
ber of SWDs may  vary between 15–40/20–80/6–90 (per hour) in
WAG/Rij rats, GAERS rats and Long Evans rats depending on the
time of the day and age of animals (Akman et al., 2010; Coenen
and Van Luijtelaar, 2003; Depaulis and Van Luijtelaar, 2005; Polack
and Charpier, 2006; Shaw, 2004). To avoid the modulatory effect
of age and sleep-wake cycle on SWD  number, electrophysiological
recordings were carry out on eight months old animals (±1 week)
between 4.00 PM and 8.00 PM.  In this relatively short period of cir-
cadian activity, the LPS evoked changes in SWD  number are not the
consequence of reduced waking state (Kovács et al., 2006). After
the different treatments, the EEG recording periods were split into
60 min  sections and evaluated separately (Kovács et al., 2006). The
SWDs (Fig. 1a, c and e) were selected, and SWD  numbers were mea-
sured in all animal groups (groups 1–12; Table 1). The durations
of SWDs were also measured in animals treated i.p. LPS injection
alone (groups 1–6; Table 1). Both i.p. injection and handling evoked
stress could inﬂuence SWD  number during ﬁrst 30 min  (Depaulis
and Van Luijtelaar, 2005; Kovács et al., 2006, 2012). Consequently,
the ﬁrst half hour of data after the i.p. injections were not included
into the analysis. In relation to individually different SWD  num-
ber and duration (Kovács et al., 2006; Polack and Charpier, 2006;
Shaw, 2004), the changes in SWD  numbers and duration were
expressed in percentage of average control measures (three-day
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Table  1
The treatment protocol of the twelve animal groups carried out WAG/Rij rats, GAERS rats and Long Evans rats. Abbreviations: IND, indomethacin; i.p., intraperitoneal; LPS,
lipopolysaccharide; PTC day, post-treatment control day.
Animal groups Experimental design
1–3 days 4th day 5th day (PTC day)
Group 1 (WAG/Rij; n = 5) 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later,
50 g/kg LPS in 1 ml saline i.p.
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 2 (WAG/Rij; n = 5) 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later,
350 g/kg LPS in 1 ml saline i.p.
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 3 (GAERS; n = 5) 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later,
50 g/kg LPS in 1 ml saline i.p.
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 4 (GAERS; n = 5) 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later,
350 g/kg LPS in 1 ml saline i.p.
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 5 (Long Evans; n = 5) 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later,
50 g/kg LPS in 1 ml saline i.p.
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 6 (Long Evans; n = 5) 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p. 1st treatment: 2 ml  saline i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later,
350 g/kg LPS in 1 ml saline i.p.
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 7 (WAG/Rij; n = 5) 1st treatment: 2 ml  5% (v/v)
ethanol solution i.p.
1st treatment: 10 mg/kg IND in
2  ml  5% (v/v) ethanol solution i.p.
1st treatment: 2 ml  5% (v/v)
ethanol solution i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later, 1 ml
saline i.p.
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 8 (WAG/Rij; n = 5) 1st treatment: 2 ml  5% (v/v)
ethanol solution i.p.
1st treatment: 10 mg/kg IND in
2  ml  5% (v/v) ethanol solution i.p.
1st treatment: 2 ml  5% (v/v)
ethanol solution i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later,
50 g/kg LPS in 1 ml saline i.p
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 9 (GAERS; n = 5) 1st treatment: 2 ml  5% (v/v)
ethanol solution i.p.
1st treatment: 10 mg/kg IND in
2  ml  5% (v/v) ethanol solution i.p.
1st treatment: 2 ml  5% (v/v)
ethanol solution i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later, 1 ml
saline i.p.
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 10 (GAERS; n = 5) 1st treatment: 2 ml  5% (v/v)
ethanol solution i.p.
1st treatment: 10 mg/kg IND in
2  ml  5% (v/v) ethanol solution i.p.
1st treatment: 2 ml  5% (v/v)
ethanol solution i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later,
50 g/kg LPS in 1 ml saline i.p
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 11 (Long Evans; n = 5) 1st treatment: 2 ml  5% (v/v)
ethanol solution i.p.
1st treatment: 10 mg/kg IND in
2  ml  5% (v/v) ethanol solution i.p.
1st treatment: 2 ml  5% (v/v)
ethanol solution i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
2nd treatment: 30 min  later, 1 ml
saline i.p.
2nd treatment: 30 min  later,
1 ml saline i.p.
Group 12 (Long Evans; n = 5) 1st treatment: 2 ml  5% (v/v) 1st treatment: 10 mg/kg IND in 1st treatment: 2 ml  5% (v/v)
c
m
2
a
m
2
2
7
o
T
1
t
o
(
s
g
3
t
o
2
(ethanol solution i.p.
2nd  treatment: 30 min later,
1 ml  saline i.p.
ontrol period) and evaluated by ANOVA. Data are expressed as
eans ± S.E.M.
.2.3. Experimental design: application of LPS and IND
Animals were assigned into twelve groups (n = 5–5) and treated
s follows (Table 1). To establish average control SWD  levels, ani-
als were injected for three days (three-day control period) with
 ml  saline i.p. (1st injection, 1–3 days, groups 1–6) (Table 1) or with
 ml  5% (v/v) ethanol solution i.p. (1st injection, 1–3 days, groups
–12) (Table 1) because IND (Sigma, Germany) which was injected
n the fourth day dissolves in 5% (v/v) ethanol solution (Table 1).
hirty min  later, all animals received 1 ml  saline i.p. (2nd injection,
–3 days, groups 1–12) (Table 1).
The animals in groups 1–6 received 2 ml  saline i.p. (1st injec-
ion) and 30 min  later, 50 g/kg LPS in 1 ml  saline (groups 1, 3, 5)
r 350 g/kg LPS in 1 ml  saline (groups 2, 4, 6) were i.p. injected
2nd injection) on the fourth day (Table 1). To examine the pos-
ible long lasting effects of LPS, on the ﬁfth day, all animals of
roups 1–6 were injected with 2 ml  saline i.p. (1st injection) and
0 min  later (2nd injection) with 1 ml  saline (post-treatment con-
rol experiments/day: PTC day) (Table 1). In case of the groups 7–12,
n the fourth day, animals received 10 mg/kg IND (i.p.) dissolved in
 ml  5% (v/v) ethanol in saline (1st injection), which was followed
2nd injection) by 1 ml  saline i.p. (groups 7, 9, 11) or by 50 g/kg2  ml  5% (v/v) ethanol solution i.p. ethanol solution i.p.
2nd treatment: 30 min  later,
50 g/kg LPS in 1 ml saline i.p
2nd treatment: 30 min  later,
1 ml saline i.p.
LPS in 1 ml  saline i.p. (groups 8, 10, 12) 30 min  later (Table 1). In
animals of groups 7–12, on the ﬁfth day, a post-treatment control
experiment was also performed by i.p. injection of 2 ml  5% (v/v)
ethanol solution (1st injection) and 1 ml  saline (2nd injection; PTC
day) (Table 1).
3. Results
3.1. Effect of LPS on body temperature and on SWD number and
SWD  duration
Intraperitoneal application of 50 g/kg LPS and 350 g/kg LPS
initially decreased and increased body temperature for about
40–60 min  after injection, respectively, following by a rapid eleva-
tion and reduction of body temperature similarly in all investigated
rat strains and groups (Fig. 2a–f; Table 1: groups 1–6). The body
temperature continuously increased (50 g/kg LPS) and decreased
(350 g/kg LPS) and reached their highest levels (about 0.6–0.8 ◦C
above basal level) between 120 and 190 min  (50 g/kg LPS, Fig. 2a,
c and e) and lowest levels (about 0.7–0.9 ◦C below basal level) at
140 min  (WAG/Rij rats), 210 min  (GAERS rats) and 200 min  (Long
Evans rats) (350 g/kg LPS, Fig. 2b, d and f). Body temperature
remained elevated (50 g/kg LPS) or decreased (350 g/kg LPS)
until the end of the measurement (270 min).
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 free
n
(
eFig. 1. Typical SWDs (a, c, e) and their power spectrum (b, d, f) recorded fromBoth doses of LPS (i.p. 50 g/kg LPS and 350 g/kg LPS) sig-
iﬁcantly increased the number of SWDs in all animal strains
Fig. 3a–f; Table 1: groups 1–6). However, several small differ-
nces were observed among the three rat strains in relation toly moving WAG/Rij rats, GAERS rats and Long Evans rats on the control days.the time course of LPS evoked effects on SWD  number. After
the rapid elevation of SWD  number in WAG/Rij rats and Long
Evans rats (WAG/Rij and Long Evans; 30–90 min  after injec-
tion: 193.5 ± 17.9% and 169.3 ± 9.9% compared to the three-day
Z. Kovács et al. / Brain Research Bulletin 104 (2014) 7–18 11
F  2), G
i e of i.p
c
2
2
l
2ig. 2. LPS induced body temperature changes in WAG/Rij rats (a: group 1; b: group
.p.  injection of two  doses of LPS (50 g/kg and 350 g/kg). Arrows indicate the tim
ontrol period), the SWD  number increased until 90–150/150 -
10 min  (WAG/Rij and Long Evans; 90–150 min: 314.7 ± 38.8% and
82.1 ± 39.4%, 150–210 min: 305.9 ± 57.3% and 307.2 ± 38.2%) fol-
owing slight decrease in SWD  numbers (WAG/Rij and Long Evans;
75.8 ± 37.4% and 279.8 ± 52.2) between 210 and 270 min  (Fig. 3aAERS rats (c: group 3; d: group 4) and Long Evans rats (e: group 5; f: group 6) after
. injection (0 min).
and e). However, in GAERS rats, SWD  number remained at sim-
ilarly high level between 30–90 (206.6 ± 24.5%) and 90–150 min
(208.3 ± 23.3%) followed by a slight decrease in the number of
SWDs (150–210 min: 171.5 ± 26.7%, 210–270 min: 163.2 ± 21.2%)
(Fig. 3c). In case of higher dose of LPS (350 g/kg LPS), the
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Fig. 3. Effects of 50 g/kg and 350 g/kg LPS on SWD  number in WAG/Rij rats (a: 50 g/kg LPS, group 1; b: 350 g/kg LPS, group 2), GAERS rats (c: 50 g/kg LPS, group 3; d:
3 g LPS,
c ed in 
L * labe
S
(
4
(
s50  g/kg LPS, group 4), and Long Evans rats (e: 50 g/kg LPS, group 5; f: 350 g/k
ontrol days (PTC day, gray columns). The changes in SWD  numbers were express
PS,  lipopolysaccharide; PTC day, post-treatment control day. * Labels p < 0.05 and *
WD  numbers (i) increased continuously between 30 and 210 min
30–90 min: 197.2 ± 26.9%, 90–150 min: 301.8 ± 46.5%, 150–210:
19.4 ± 54.7%) after i.p. injection following a rapid decrease
210–270 min: 169.1 ± 10.0%) in WAG/Rij rats, (ii) remained at
imilarly elevated level between 30 and 270 min  (30–90 min: group 6) on the days of LPS treatment (black columns) and on the post-treatment
percentage of average control measures (three-day control period). Abbreviations:
ls p < 0.005 level of signiﬁcance.
207.9 ± 25.6%, 90–150 min: 217.6 ± 20.6%, 150–210: 210.4 ± 28.5%,
210–270 min: 204.7 ± 28.9%) in GAERS rats and (iii) increased for
150 min  (30–90 min: 189.0 ± 47.1%, 90–150 min: 374.4 ± 78.7%)
and remained at high level (150–210: 346.0 ± 80.5%, 210–270 min:
400.9 ± 86.6%) in Long Evans rats (Fig. 3b, d and f). In addition, the
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igher dose of LPS (350 g/kg LPS) was not able to evoke higher
ncrease in SWD  number than the smaller dose (50 g/kg LPS) did
n GAERS rats (Fig. 3c and d). After i.p. injection of 50 g/kg LPS,
n the PTC day, the SWD  number returned to the baseline level in
ll animal strains (Fig. 3a, c and e). In relation to injection of the
igher dose of LPS (350 g/kg LPS), on the PTC day, decreased SWD
umbers were detected between 30 and 90 min  in WAG/Rij rats
61.4 ± 20.4%) and Long Evans rats (61.8 ± 14.3%) whereas only a
light lowering in SWD  number (86.3 ± 12.5%) was  observed in the
rst measuring hour in GAERS rats (Fig. 3b, d and f).
The total time of SWDs signiﬁcantly increased in parallel with
he change in SWD  number between 30 and 270 min  after LPS injec-
ion in WAG/Rij rats, GAERS rats and Long Evans rats, which is
n agreement with the result that average time of SWDs did not
hange signiﬁcantly (Fig. 4; Table 1: groups 1–6).
.2. Effect of IND alone and in combination with LPS on SWD
umber and body temperature
Indomethacin (10 mg/kg i.p.) alone signiﬁcantly decreased the
umber of SWDs in the ﬁrst 2 h of the recordings in WAG/Rij
ats (30–90 min: 31.0 ± 9.2%, 90–150 min: 45.8 ± 14.6%), GAERS
ats (30–90 min: 46.0 ± 11.2%, 90–150 min: 62.8 ± 14.6%) and Long
vans rats (30–90 min: 26.0 ± 6.2%, 90–150 min: 55.8 ± 11.6%) rats
Fig. 5a, c and e: 10 mg/kg IND; Table 1: groups 7, 9 and 11). By
retreatment with IND (10 mg/kg i.p.) 30 min  before the i.p. LPS
njection (50 g/kg) SWD  number increasing effect of LPS was  com-
letely abolished in all animal strains (Fig. 5a, c and e: IND + LPS;
able 1: groups 8, 10 and 12).
Indomethacin (10 mg/kg i.p.) injected alone had no effect on
ody temperature in any animal strain (Fig. 5b, d and f: 10 mg/kg
ND; Table 1: groups 7, 9 and 11) whereas IND (10 mg/kg i.p.) pre-
reatment 30 min  before LPS injection (50 g/kg LPS i.p.) abolished
he LPS evoked increase in body temperature (Fig. 5b, d and f:
ND + LPS; Table 1: groups 8, 10 and 12).
. Discussion
The major ﬁnding of our study was that we  were able to
trengthen our previous results in WAG/Rij rats and extend them to
wo other absence epileptic rats (GAERS and Long Evans), such as:
i) i.p. injection of single doses of LPS enhanced the seizure activity
nd changed the body temperature dose-dependently, and (ii) IND
retreatment abolished the LPS treatment evoked changes in body
emperature and SWD  number.
The genetically absence epileptic WAG/Rij rats and GAERS rats
re well established models of human absence epilepsy (Depaulis
nd Van Luijtelaar, 2005; Van Luijtelaar et al., 2011). It is inter-
sting to note that not only WAG/Rij rats and GAERS rats but also
ong Evans rats produce SWDs: spontaneous high-voltage rhyth-
ic  spike (HVRS) discharges of Long Evans rats in EEG recordings
ay  be considered as SWDs as was demonstrated by analysis
f pharmacological, behavioral and EEG features of HVRS activ-
ty (Depaulis and Van Luijtelaar, 2005; Huang et al., 2012; Polack
nd Charpier, 2006; Shaw, 2004, 2007; Shaw et al., 2009; Van
uijtelaar et al., 2011). However, additional studies (e.g., pharma-
ological and electrophysiological) are needed to investigate the
imilarities/differences in the features of absence epileptic activity
etween WAG/Rij rats, GAERS rats and Long Evans rats in order to
nclude the Long Evans rat strain in the widely accepted models of
uman absence epilepsy. According to literature, Long Evans rats
ay  be considered as a model animal of absence epilepsy only to
ome extent at the moment (Depaulis and Van Luijtelaar, 2005;
uang et al., 2012; Kovács et al., 2013; Polack and Charpier, 2006;
haw, 2004, 2007; Shaw et al., 2009; Van Luijtelaar et al., 2011). ABulletin 104 (2014) 7–18 13
typical SWD  contains train of spikes and slow waves starting and
ending with spikes in all absence epileptic rats, but some differ-
ences in features of SWDs in GAERS rats, WAG/Rij rats and Long
Evans rats have been revealed. For example, ﬁrst SWDs  emerge
after 30th days and between 60 and 80 days in GAERS rats and
WAG/Rij rats, respectively (Akman et al., 2010; Coenen and Van
Luijtelaar, 2003; Depaulis and Van Luijtelaar, 2005). There are also
similarities with some differences between the 3 strains as far as
the mechanisms of SWDs. It has been demonstrated, that (i) several
neurotransmitter systems are involved in the pathophysiological
processes leading to absence epileptic seizures and their mainte-
nance/recurrence such as glutamatergic system, GABAergic system,
dopaminergic and nucleosiderg system in GAERS rats, WAG/Rij rats
and Long Evans rats (Bazyan and Van Luijtelaar, 2013; Depaulis and
Van Luijtelaar, 2005; Kovács et al., 2013, 2014; Li et al., 2006; Polack
and Charpier, 2006), (ii) the effects of anti-epileptic drugs on SWDs
were similar in GAERS rats, WAG/Rij rats and Long Evans rats (e.g.,
ethosuximide, and valproate decreased the number of SWDs) (Chen
et al., 2011; Depaulis and Van Luijtelaar, 2005; Shaw, 2004, 2007),
(iii) sodium channel (Nav1.1 and Nav1.6) expression was  selec-
tively increased in the somatosensory cortex of WAG/Rij rats in
relation to age-dependent increase in seizure number and duration
(Klein et al., 2004), (iv) selective decrease in thalamic (e.g., reticular
thalamic nucleus) and cortical (e.g., somatosensory cortex) GABA(A)
receptor subunits such as reduction of 3 subunit of GABA(A) recep-
tor in reticular thalamic nucleus of WAG/Rij rats (Liu et al., 2007)
may  have a role in the pathophysiology of absence epilepsy in
Long Evans rats, WAG/Rij rats and GAERS rats (Li et al., 2006;
Spreaﬁco et al., 1993), (v) mRNA levels for most GABA(B(1)) subunits
were lower in WAG/Rij neocortex than in cortex of control non-
epileptic rats, which can contribute to neocortical hyperexcitability
and SWD  generation (Merlo et al., 2007) whereas GABA(B(1)) sub-
unit mRNA levels were higher and lower in the somatosensory
cortex and ventrobasal thalamic nuclei of GAERS rats, respec-
tively, compared with control animals (Princivalle et al., 2003), (vi)
decreased alpha-amino-3-hydroxy-5-methyl-4-isoazolepropionic
acid receptor (AMPA; AMPA-GluR4) and N-methyl-d-aspartate
receptor (NMDA; NMDA-NR1) expression in the cortical focus
of WAG/Rij animals (compared with non-epileptic control rats)
and increased AMPA-GluR1/2 expression in GAERS rats in the
somatosensory cortex may  be in relation to hyperexcitability in
somatosensory cortex and to SWD  initiation (Van de Bovenkamp-
Janssen et al., 2006; Kennard et al., 2011), (vii) reduction of
group-I metabotropic glutamate receptors (mGlu1 receptors) in
ventrobasal thalamic nuclei and increased expression of group-II
metabotropic glutamate receptors (mGlu2/3 receptors) in WAG/Rij
rat somatosensory cortex and ventrobasal thalamic nuclei may  be
involved in the generation of SWDs (Ngomba et al., 2005, 2011),
(viii) levels of dopaminergic (e.g., D1 and D2) receptor expression
in different striatal and cortical structures implicated in control
of absence epilepsy were changed in WAG/Rij rats and GAERS
rats (Birioukova et al., 2005; Jones et al., 2010), (ix) expression of
hyperpolarization-activated cyclic nucleotide-gated cation chan-
nel (HCN; HCN1) was reduced in somatosensory cortex in WAG/Rij
rats and increased in thalamocortical cells in both WAG/Rij rats
and GAERS rats in relation to development and onset of cortical
hyperexcitability and epileptogenesis as well as prolonged gener-
ation and termination of SWDs (Budde et al., 2005; Kuisle et al.,
2006; Strauss et al., 2004) and (x) changes in T-type Ca2+ channels
(e.g., increase in expression of T-type Ca2+ channels and muta-
tions of different T-type Ca2+ channel genes in thalamic areas)
may  be in relation to increased absence epileptic activity in both
WAG/Rij rats and GAERS rats (Broicher et al., 2008; Powell et al.,
2009). In spite of some differences revealed, the anatomical, neuro-
chemical and electrophysiological background of seizure initiation,
seizure maintenance and cessation may  be similar in GAERS rats,
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Fig. 4. Lipopolysaccharide (50 g/kg LPS and 350 g/kg LPS i.p.) induced changes in total SWD  time (50 g/kg LPS: black columns, 350 g/kg LPS: gray columns) and in
average  SWD  time (50 g/kg LPS: stripped columns, 350 g/kg LPS: open columns) in WAG/Rij rats (group 1 and group 2), GAERS rats (group 3 and group 4) and Long
Evans  rats (group 5 and group 6). The changes in SWD  duration were expressed in percentage of average control measures (three-day control period). Abbreviations: LPS,
lipopolysaccharide; SWD: spike–wave discharge. * Labels p < 0.05 level of signiﬁcance.
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Fig. 5. Effect of i.p. IND alone (10 mg/kg IND, stripped columns) and i.p. IND (10 mg/kg) in combination with 50 g/kg i.p LPS (IND + LPS, open columns) on SWD  number
in  WAG/Rij rats (a: group 7 and group 8), GAERS rats (c: group 9 and group 10) and Long Evans rats (e: group 11 and group 12). The ﬁgure also shows the effect of i.p. IND
(10  mg/kg IND, ﬁlled circles) and combined application of i.p. IND (10 mg/kg) and 50 g/kg i.p LPS (IND + LPS, open triangles) on body temperature in WAG/Rij rats (b: group
7  and group 8), GAERS rats (d: group 9 and group 10) and Long Evans rats (f: group 11 and group 12). For comparison, effect of i.p. injected 50 g/kg LPS alone on SWD
number (50 g/kg LPS, black columns in: a, group 1; c, group 3; e, group 5) and on body temperature (50 g/kg LPS, ﬁlled squares in: b, group 1; d, group 3; f, group 5) were
plotted  again. Arrows indicate the i.p. injection (0 min; b, d and f). Abbreviations: IND, indomethacin; LPS, lipopolysaccharide. * Labels p < 0.05 and ** labels p < 0.005 level of
signiﬁcance.
1 earch 
W
a
z
t
c
E
a
V
c
S
b
L
I
n
m
C
M
p
1
o
n
i
a
R
a
a
c
V
e
h
V
(
(
e
r
(
c
e
2
i

V
t
(
V
s
a
e
r
t
i
t
T
r
c
a
d
c
2
b
I
t
2
a6 Z. Kovács et al. / Brain Res
AG/Rij rats and Long Evans rats: the spontaneously generated
bsence-like seizures arise from the hyperexcitable focal cortical
one (cortical focus) in the somatosensory cortex, rapidly spread
o other cortical and thalamic areas via intracortical networks and
orticothalamic connections, respectively, and manifest in SWDs in
EG (Chen et al., 2011; Coenen and Van Luijtelaar, 2003; Depaulis
nd Van Luijtelaar, 2005; Polack and Charpier, 2006; Shaw, 2004;
an Luijtelaar et al., 2011). It was demonstrated, that the corti-
al focus leads the thalamus during the ﬁrst 500 ms  of the SWD.
ubsequently, the cortical focus and the thalamus drive each other
y cortico-thalamo-cortical oscillatory networks (Depaulis and Van
uijtelaar, 2005; Meeren et al., 2002).
Lipopolysaccharide evoked effects may  be mediated by the
L-1, COX-2/prostaglandin E2 (PGE2) system and IL-1R/TLR sig-
aling in the CNS. It was  revealed that different doses of LPS
ay  evoke changes in body temperature through the IL-1,
OX-2/PGE2 system (Huang et al., 2010; Kovács et al., 2006;
lodzikowska-Albrecht et al., 2007), which can be inhibited by
receding application of the COX-2 inhibitor IND (Hashimoto et al.,
998; Kovács et al., 2006, 2011). Indomethacin alone had no effect
n body temperature whereas its combined injection with LPS sig-
iﬁcantly decreased fever (Dogan et al., 2002; Kovács et al., 2011).
The i.p. injected LPS can induce cerebral inﬂammation via
ncreased blood level of cytokines and inﬂammatory mediators
nd through direct action on brain cells (Kovács et al., 2006;
iazi et al., 2010; Rivest, 2003; Vezzani and Granata, 2005). The
ctivated innate immune system (glycosylphosphatidylinositol-
nchored glycoprotein CD14, accessory protein MD-2 and TLR4)
an generate immune response in the brain (Vezzani et al., 2011;
ezzani and Granata, 2005). Lipopolysaccharide evoked increased
xpression in TLR4, IL-1 and TNF- in the brain within several
ours (Eriksson et al., 2000; Goralski et al., 2005; Turrin et al., 2001;
ezzani et al., 2011) and glial release of proinﬂammatory cytokines
e.g., IL-1 and TNF-) through TLR4 was also demonstrated
Mlodzikowska-Albrecht et al., 2007; Rodgers et al., 2009; Vezzani
t al., 2011). IL-1 and TNF- may  diminish the chloride cur-
ent and may  enlarge excitatory glutamatergic neurotransmission
Mlodzikowska-Albrecht et al., 2007; Vezzani and Granata, 2005)
ausing decreased seizure threshold and enhanced neuronal hyper-
xcitability (Riazi et al., 2010; Rodgers et al., 2009; Vezzani et al.,
011, 2013). In addition, GABA(A)-mediated inhibition decreasing
nﬂuence and AMPA-dependent excitation increasing effect of TNF-
 were also demonstrated (Mlodzikowska-Albrecht et al., 2007;
ezzani et al., 2008). Imbalanced intracortical inhibitory and exci-
atory mechanisms result in cortical hyperexcitability during SWDs
Chen et al., 2011; Coenen and Van Luijtelaar, 2003; Depaulis and
an Luijtelaar, 2005; Van Luijtelaar et al., 2011). Thus, as a con-
equence of LPS/cytokine evoked increase in neuronal excitability
nd IL-1R expression on thalamic neurons and in the cortex (Wang
t al., 1997; Yabuuchi et al., 1994), i.p. LPS injection evoked IL-1
elease can enhance the excitation in the thalamo-cortical/cortico-
halamic circuitry, which could aggravate epileptic seizure activity
n absence epileptic rats (Kovács et al., 2006; Snead, 1995). Lit-
le is known about the exact role of cytokines, such as IL-1 and
NF- in absence epilepsy genesis/modulation in absence epileptic
ats. Thus, explanation of LPS evoked small differences in the time
ourse of LPS evoked effects on SWD  number and body temperature
mong the three rat strains is not straightforward. However, it was
emonstrated that the LPS evoked increase in pro-inﬂammatory
ytokines can increase absence epileptic activity between 30 and
70 min  after injection independently from inﬂammation induced
ody temperature changes (Kovács et al., 2006, 2011), in which
L-1 may  be one of the main pro-epileptic (pro-absence) media-
ors possibly via GABAergic neurotransmission (Van Luijtelaar et al.,
012) in WAG/Rij animals. Nevertheless, the presence of reactive
strocytes in the GAERS cortex and thalamus before the onset ofBulletin 104 (2014) 7–18
absence epileptic seizures (Dutuit et al., 2000) and IL-1 induction
in reactive astrocytes of adult GAERS rat somatosensory cortex at
the onset of SWDs and the contribution of IL-1 to SWD  occurrence
were also demonstrated in GAERS rats (Akin et al., 2011). Thus, we
can conclude that pro-inﬂammatory cytokines may  have aggravat-
ing inﬂuence on absence epileptic activity (genesis and recurrence
of SWDs) at least in the investigated two  rat models (WAG/Rij,
GAERS) of absence epilepsy and also in Long Evans rats.
It was demonstrated that (i) LPS and pro-inﬂammatory
cytokines can induce the expression of COX-2 mRNA (Cao et al.,
1995; Vezzani and Granata, 2005), (ii) prostaglandins may have a
role in the seizure threshold decreasing effect of LPS (Sayyah et al.,
2003), (iii) PGE2 has proconvulsant effect (Sayyah et al., 2003) and
(iv) the T-type Ca2+ channel evoked Ca2+ current (which has a role in
the genesis of absence seizure) decreasing effect of IND may  dimin-
ish absence epileptic activity in WAG/Rij rats, GAERS rats and Long
Evans rats (Depaulis and Van Luijtelaar, 2005; Polack and Charpier,
2006; Shin, 2006; Van Luijtelaar et al., 2000). Thus, indomethacin
may  exert its effect on absence epileptic activity (e.g. SWD  number
decreasing effect injected alone and SWD  number abolishing inﬂu-
ence injected before LPS) via inhibition of both T-type Ca2+ channel
and COX-2 (Kovács et al., 2006, 2011) in the three animal strains
investigated.
In conclusion,  we have demonstrated that i.p. LPS and its com-
bination with i.p. IND changed the number and duration of SWDs
and body temperature in WAG/Rij rats, GAERS rats and also in Long
Evans rats suggesting that the same neuroinﬂammatory processes
are in the background. In addition, the results of this study also sug-
gest that Long Evans rat strain could be an animal model of human
absence epilepsy as the experimental results obtained in these
rats are similar to the experimental results obtained in the well-
known animal models (WAG/Rij and GAERS) of human absence
epilepsy. These results extend our previous data suggesting that
our methods based on LPS injection into freely moving absence
epileptic rats are broadly applicable across rat models of absence
epilepsy (such as WAG/Rij rats and GAERS rats) and Long Evans
rats, to investigate the links between the activation of the inﬂam-
matory/cytokine system, the excitability of neuronal networks and
the absence epileptic activity as well as the beneﬁcial and adverse
effects of new anti-inﬂammatory/anti-epileptic drugs, such as TLR4
antagonists (Maroso et al., 2010).
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